Kineta Market Cap 2014-2024 | KANT

Kineta market cap history and chart from 2014 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Kineta market cap as of September 20, 2024 is $0B.
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.000B $0.005B
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
Stock Name Country Market Cap PE Ratio
Plum Acquisition I (VEEA) United States $0.124B 0.00
Pono Capital Two (SBC) United States $0.036B 0.00
ANEW Medical (KLTO) United States $0.014B 0.00
Tupperware Brands (TUPBQ) United States $0.003B 0.00